Om

Freenome Inc. is a biotechnology company focused on early cancer detection through blood-based screening tests. The company develops a multiomics platform that combines molecular biology, artificial intelligence, and machine learning to analyze subtle biological signals associated with cancer. Its current product work centers on noninvasive screening tools for colorectal cancer, along with broader blood tests aimed at detecting multiple cancers and other diseases at earlier, more treatable stages. Freenome’s technology is designed to support clinical screening programs and improve access to cancer detection through a standard blood draw, making it relevant to diagnostics, preventive care, and precision medicine. Headquartered in Brisbane, California, Freenome operates at the intersection of biotechnology, data science, and medical diagnostics, with a focus on simplifying how cancer is identified in routine healthcare settings.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I FREENOME MED ENDAVU: Køb Freenome ($FRNM) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Freenome, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.